Caryophyllene

The paper specifies beta-caryophyllene

Caryophyllene is used for related sesquiterpenes, while the main paper here specifies trans-beta-caryophyllene, also written (E)-beta-caryophyllene. That is the detail to preserve when a chemistry report is compared with the study. The name itself does not identify a product or patient response.

CB2 activity was studied across several models

The primary study examined (E)-beta-caryophyllene at the CB2 receptor, then measured signalling in receptor systems, primary human monocytes and mouse experiments. Those are different pieces of receptor, human-cell and animal evidence. None of them was a clinical trial of a prescribed cannabis product. A secondary plant-chemistry reference supports the name caryophyllene, not a treatment claim.

The label still describes composition

If caryophyllene appears in a certificate of analysis, the useful questions are which isomer was measured, by which method and at what concentration. The line does not show absorbed exposure, the behaviour of the complete formulation or an individual response. The MCPH terpene reference is a better place to compare names than a marketing effect chart.

The cited findings can support further receptor and model research. They do not establish clinical pain relief, anti-inflammatory treatment or the effect of a caryophyllene-containing cannabis product.

Related conditions

• Arthritis and joint pain
• Inflammatory bowel disease
• Neuropathic pain

Sources

• Beta-caryophyllene at the CB2 receptor (primary receptor, human-cell and mouse study, PMID 18574142, DOI 10.1073/pnas.0803601105).